T-cell masthead image

Resources

Paper

Dusquetide: Reduction in oral mucositis associated with enduring ancillary benefits in tumor resolution and decreased mortality in head and neck cancer patients

  • PDF (240.80 KB)
Kudrimoti M, Curtis A, Azawi S, Worden F, Katz S, Adkins D, Bonomi M, Scott Z, Elder J, Sonis ST, Straube R, Donini O. Dusquetide: Reduction in oral mucositis associated with enduring ancillary benefits in tumor resolution and decreased mortality in head and neck cancer patients. Biotech Reports. 2017; 15:24-26.
Publication

BioWorld Today Ricin Toxin Program Review

In a recent article in BioWorld Today, the Soligenix ricin toxin vaccine program was reviewed, including comments from Dr. Oreola Donini, Chief Scientific Officer of Soligenix.
Presentation

Innate Defense Regulators: Agnostic Therapy for Antibiotic Resistant Disease

Donini O. Innate Defense Regulators: Agnostic Therapy for Antibiotic Resistant Disease – “Supercharging existing and new antibiotic therapies”. Presentation at the 2017 Superbugs & Superdrugs Meeting. March 20-21, 2017.
Presentation

Innate Defense Regulators: Agnostic Therapy for Antibiotic Resistant Disease-Supercharging existing and new antibiotic therapies

Donini O. Innate Defense Regulators: Agnostic Therapy for Antibiotic Resistant Disease – “Supercharging existing and new antibiotic therapies”. Presentation at the 2017 Superbugs & Superdrugs Meeting. March 20-21, 2017.
Paper

Dusquetide: A novel innate defense regulator demonstrating a significant and consistent reduction in the duration of oral mucositis in preclinical data and a randomized, placebo-controlled phase 2a clinical study

  • External Link
Kudrimoti M, Curtis A, Azawi S, Worden F, Katz S, Adkins D, Bonomi M, Elder J, Sonis S, Straube S, Donini O. Dusquetide: A novel innate defense regulator demonstrating a significant and consistent reduction in the duration of oral mucositis in preclinical data and a randomized, placebo-controlled phase 2a clinical study. J Biotech 2016; 239: 115-125.
Paper

Dusquetide: A novel innate defense regulator demonstrating a significant and consistent reduction in the duration of oral mucositis in preclinical data and a randomized, placebo-controlled phase 2a clinical study

  • External Link
Kudrimoti M, Curtis A, Azawi S, Worden F, Katz S, Adkins D, Bonomi M, Elder J, Sonis S, Straube S, Donini O. Dusquetide: A novel innate defense regulator demonstrating a significant and consistent reduction in the duration of oral mucositis in preclinical data and a randomized, placebo-controlled phase 2a clinical study. J Biotech 2016; 239: 115-125.
Poster

Orphan Disease, Biodefense and the Animal Rule: A Thermostabilized Ricin Toxin Vaccine

  • PDF (811.10 KB)
Donini O, Haulenbeek A, Arumugham R, Schaber C. Orphan Disease, Biodefense and the Animal Rule: A Thermostabilized Ricin Toxin Vaccine. Poster Presentated at the National Organization for Rare Diseases (NORD) Rare Diseases and Orphan Products Breakthrough Summit.
Presentation

Dusquetide: Innate Defense Regulation as a Novel Approach to Antibiotic-Resistant Infection

Donini, O. Dusquetide: Innate Defense Regulation as a Novel Approach to Antibiotic-Resistant Infection. Presentation at BARDA TechWatch Meeting. August 2016.